[{"id":"d33f29f1-147b-4dc5-a399-0e2be76f607a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05198505","created_at":"2022-01-20T15:53:48.525Z","updated_at":"2024-07-02T16:36:11.183Z","phase":"Phase 1","brief_title":"Clinical Trial of TQB2868 Injection in Subjects With Advanced Malignant Tumors","source_id_and_acronym":"NCT05198505","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","biomarkers":" PD-L1 • TGFB1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TQB2868"],"overall_status":"Recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 04/27/2022","start_date":" 04/27/2022","primary_txt":" Primary completion: 06/01/2023","primary_completion_date":" 06/01/2023","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2022-05-02"}]